There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Satsuma Pharmaceuticals (STSA – Research Report) and Dyadic International (DYAI – Research Report) with bullish sentiments.
Satsuma Pharmaceuticals (STSA)
In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Satsuma Pharmaceuticals, with a price target of $13.00. The company’s shares closed last Monday at $0.79.
According to TipRanks.com, Ear is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Satsuma Pharmaceuticals with a $15.80 average price target, a 290.1% upside from current levels. In a report issued on November 4, SVB Securities also maintained a Buy rating on the stock with a $15.00 price target.
See today’s best-performing stocks on TipRanks >>
Dyadic International (DYAI)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Dyadic International, with a price target of $6.00. The company’s shares closed last Friday at $1.89, close to its 52-week low of $1.58.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of
Currently, the analyst consensus on Dyadic International is a Moderate Buy with an average price target of $6.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on STSA:
